文献速递肾癌与肾肿瘤

免疫检查点抑制剂时代的减瘤性肾切除术:回到未来?

Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future?
PubMed 文献 · BJU Int · 2026-02-11

本文通过叙述性综述检索PubMed 2015年1月至2025年5月的英文文献,最终纳入12项回顾性研究,比较转移性肾细胞癌患者接受含免疫检查点抑制剂方案时联合或不联合减瘤性肾切除术的结局。其中6项研究显示联合减瘤性肾切除术有生存获益,风险比为0.19至0.63,该发现在 upfront 减瘤性肾切除术亚组中一致;但回顾性设计、选择偏倚和永恒时间偏倚限制结论。

要点

  • 6项回顾性研究显示ICI联合CN风险比0.19至0.63的生存获益
  • upfront CN亚组中获益结果保持一致
  • NORDIC-SUN、SWOG-1931和SEVURO-CN等III期随机试验正在评估CN时机

核心结论

  • 在ICI时代需重新审视减瘤性肾切除术的重要性,可能源于肿瘤负荷对抗癌免疫的影响及ICI对原发肿瘤疗效有限。
  • 未来需通过随机试验明确ICI治疗背景下CN的最佳时机。

研究设计与样本

  • 叙述性综述,检索PubMed 2015年1月至2025年5月发表的英文文献。
  • 最终纳入12项回顾性研究,比较mRCC患者接受含ICI方案联合或不联合CN(upfront或deferred)的结局。

主要发现

  • 6项研究显示接受CN联合ICI的患者有生存获益,风险比为0.19至0.63。
  • 该发现在upfront CN亚组中保持一致。
  • 纳入研究的回顾性性质、固有选择偏倚和永恒时间偏倚限制确定性结论。

关键数值与推荐

  • 6项研究报告CN联合ICI的生存获益,风险比范围0.19至0.63。
  • NORDIC-SUN(NCT03977571)和SWOG-1931(PROBE;NCT04510597)评估初始ICI治疗后deferred CN的作用。
  • SEVURO-CN(NCT05753839)可能阐明ICI时代upfront CN的作用。

临床怎么用

  • 对适合安全手术的mRCC患者,ICI治疗背景下CN的作用需重新考虑,但最佳时机应由未来随机试验明确。
  • 当前证据来自回顾性研究,临床决策应结合正在进行的III期随机试验结果。

局限性

  • 纳入研究均为回顾性设计,存在固有选择偏倚和永恒时间偏倚。
  • 确定性结论有待正在进行的III期随机试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) treated with immune-checkpoint inhibitors (ICIs). METHODS: A narrative review was carried out using PubMed and searching for English articles published from January 2015 to May 2025. RESULTS: After the screening process, 12 retrospective studies comparing outcomes in patients with mRCC treated with ICI-based regimens, with or without CN (either upfront or deferred) were deemed eligible. Of those, six indicated a survival benefit for patients undergoing CN in combination with ICIs with hazards ratios ranging from 0.19 to 0.63, a finding that remains consistent within the upfront CN subgroup. However, the included studies' retrospective nature, inherent selection, and immortal time biases limit definitive conclusions. Ongoing phase III randomised trials, NORDIC-SUN (ClinicalTrials.gov identifier: NCT03977571) and Southwest Oncology Group (SWOG)-1931 (also known as PROBE; NCT04510597), are evaluating the role of deferred CN after initial ICI therapy, while the role of upfront CN in the ICI era will be likely elucidated by SEVURO-CN (NCT05753839) trial. CONCLUSION: Our findings highlight reconsidering the importance of CN in the ICI era, potentially driven by the influence of tumour burden on anti-cancer immunity and the limited efficacy of ICIs against primary tumours. Future research, ideally through randomised trials involving patients suitable for safe surgery, should aim to clarify the optimal timing of CN in the context of ICI therapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Flammia RS, Campi R, Bologna E, et al. Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future? BJU Int. 2026. PMID: 41673778. doi:10.1111/bju.70168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。